BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24348552)

  • 1. Investigation of responsiveness to thyrotropin-releasing hormone in growth hormone-producing pituitary adenomas.
    Chin SO; Rhee SY; Chon S; Hwang YC; Jeong IK; Oh S; Kim SW
    Int J Endocrinol; 2013; 2013():159858. PubMed ID: 24348552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
    Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological characteristics of growth hormone-producing pituitary adenomas are different according to responsiveness to thyrotropin-releasing hormone.
    Arita H; Kinoshita M; Oshino S; Kitamura T; Otsuki M; Kasayama S; Shimokawa T; Shimomura I; Yoshimine T; Saitoh Y
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2741-7. PubMed ID: 22569237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of thyrotrophin-releasing hormone receptor 1 messenger ribonucleic acid in human pituitary adenomas.
    Kim K; Arai K; Sanno N; Teramoto A; Shibasaki T
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):309-16. PubMed ID: 11298082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
    De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
    Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acute infusion of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in acromegalic patients.
    Díez JJ; Iglesias P; Sastre J; Gómez-Pan A
    Eur J Endocrinol; 2000 Aug; 143(2):203-11. PubMed ID: 10913939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression study of thyrotropin releasing hormone (TRH) receptor using RT-PCR: relationship to clinical and immunohistochemical phenotypes in a series of human pituitary adenomas.
    Igarashi-Migitaka J; Yamada S; Hara M; Sano T; Ozawa Y; Ohtani-Kaneko R; Hirata K
    Endocr J; 2003 Aug; 50(4):459-67. PubMed ID: 14599121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
    Biermasz NR; Smit JW; van Dulken H; Roelfsema F
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
    Chang CC; Chen FW; Hsieh HC
    Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical growth hormone response to thyrotropin-releasing hormone in acromegaly. Clinical correlations and prognostic value.
    De Marinis L; Mancini A; Zuppi P; Anile C; Maira G
    Acta Endocrinol (Copenh); 1990 Apr; 122(4):443-9. PubMed ID: 2110409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal growth hormone responses to L-dopa and thyrotropin-releasing hormone in patients with acromegaly.
    Hanew K; Aida M; Tano T; Yoshinaga K
    Tohoku J Exp Med; 1977 Mar; 121(3):197-206. PubMed ID: 404727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly].
    Tokuyama T; Yoshinari M; Okamura K; Ikenoue H; Sato K; Kuroda T; Fujishima M
    Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):65-74. PubMed ID: 1674920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRH is a tonic secretagogue in growth hormone secreting but not in nonfunctioning pituitary tumors.
    Somjen D; Tordjman K; Greenman Y; Kohen F; Ouaknine GE; Stern N
    J Endocrinol Invest; 1999 Feb; 22(2):104-8. PubMed ID: 10195376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary hormone responses to hypothalamic releasing hormones in acromegaly.
    Cantalamessa L; Reschini E; Catania A; Giustina G
    Acta Endocrinol (Copenh); 1976 Dec; 83(4):673-83. PubMed ID: 826061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly.
    Watanobe H; Tamura T
    Neuropeptides; 1995 Feb; 28(2):115-24. PubMed ID: 7746355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.